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The third International Stroke Trial (IST-3) is the largest 
(n=3035) randomised controlled trial of intravenous 
alteplase for acute ischaemic stroke to date.1 
Participants in IST-3 were older than in previous trials: 
1617 (53%) were older than 80 years of age, whereas 
only 112 patients of this age were included in eight 
previous similar trials.2 In IST-3, participants could be 
treated up to 6 h after stroke onset, but 849 (28%) were 
treated within 3 h. No signiﬁ cant eﬀ ect of alteplase was 
reported on the IST-3 primary endpoint—independence 
at 6 months (deﬁ ned as an Oxford Handicap Scale score 
of 0–2). However, in a prespeciﬁ ed ordinal analysis, 
a signiﬁ cant shift was noted in functional outcome, 
in favour of alteplase.1 A meta-analysis of individual 
patient data from nine randomised trials (including 
IST-3) showed that intravenous alteplase improved 
outcome when administered up to 4·5 h after stroke 
onset.2 The proportional beneﬁ t from alteplase 
increased with earlier treatment but was not modiﬁ ed 
by age.2 IST-3 is a landmark study because the eﬀ ects 
of alteplase could be assessed reliably in older patients 
with acute ischaemic stroke.
investigators, and this study includes a large population 
of patients with ALS and has a rigorous design. However, 
the same results need to be attained by less skilled 
investigators than those involved in this study, and the 
worldwide application of the technique will depend 
on the acquisition of new equipment and software. 
However, the study undoubtedly shows that detection of 
increased cortical excitability is a diagnostic biomarker in 
ALS, and that use of threshold tracking TMS with existing 
criteria might help to speed up the process of diagnosis.1,3
Nonetheless, despite these promising results, the 
question of disease onset is not yet resolved. Early 
signs of hyperexcitability are seen in the LMN pool; the 
presence of fasciculation potentials is the ﬁ rst change 
detected in clinically non-aﬀ ected muscles of patients 
with ALS.9 This ﬁ nding could be attributed to LMN 
activation due to increased cortical drive, but not all 
fasciculation potentials seen in the strong muscles of 
ALS patients originate in the anterior horn cell. Signs 
of corticomotoneuronal abnormality, as assessed 
by threshold tracking TMS, have been reported to 
precede signs of LMN dysfunction in the target muscle.3 
Altogether, we cannot reject the possibility that increased 
corticomotor excitability early in the disease course is a 
non-localised event in ALS and other neurodegenerative 
disorders associated with reduced GABA,10 whereas LMN 
degeneration is a topographic occurrence, ﬁ rstly aﬀ ecting 
a speciﬁ c region before spreading to other areas.9 
Electromyography is sensitive for diagnosis of ALS 
independent of the LMN or UMN disease origin;9 the same 
holds true for threshold tracking TMS.1 Early diagnosis of 
ALS and use of neurophysiology as a surrogate marker to 
detect changes in exploratory clin ical trials are imperative. 
Other groups should apply this technique in diagnosis of 
ALS. However, the mystery of the disease’s origin remains 
and demands further research. 
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Joanna Wardlaw and colleagues in the IST-3 
collaborative group report in The Lancet Neurology 
their ﬁ ndings on brain imaging.3 They sought to 
establish whether early ischaemic or pre-existing CT 
signs were associated with the eﬀ ect of alteplase on 
several outcomes, including symptomatic intracerebral 
haemorrhage and independence at 6 months. All 
images were reviewed centrally. Early ischaemic 
changes were classiﬁ ed as hyperattenuated artery, 
tissue hypoattenuation, and ischaemic lesion swelling, 
and infarct extent was also assessed; pre-existing 
signs were classiﬁ ed as old infarcts, leukoaraiosis, 
and brain atrophy. Diminished independent survival 
was associated with all early ischaemic changes 
(including tissue hypoattenuation [odds ratio 0·66, 
95% CI 0·55–0·81]), leukoaraiosis (0·72, 0·59–0·87), 
and atrophy (0·74, 0·59–0·94). Risk of symptomatic 
intracerebral haemorrhage was increased by the 
presence of old infarcts (odds ratio 1·72, 95% CI 
1·18–2·51), hypoattenuation (1·54, 1·04–2·27), and a 
hyperattenuated artery (1·54, 1·03–2·29). Multivariate 
logistic regression models including seven imaging 
signs showed that hyperattenuated arteries, large 
lesion, and leukoaraiosis each reduced the chance 
of a good outcome by 25–30%. Old infarcts and 
hyperattenuated arteries were signiﬁ cant predictors 
of symptomatic intracerebral haemorrhage. However, 
the eﬀ ect of alteplase on symptomatic intracerebral 
haemorrhage or functional outcome was not modiﬁ ed 
by any of these CT variables.3
When interpreting these ﬁ ndings, the characteristics 
of patients included in IST-3 should be considered. The 
prevalence of tissue hypoattenuation might have been 
lower than in previous studies because of the large 
number of patients older than 80 years of age. Indeed, 
ﬁ ndings from the present analysis conﬁ rm a negative 
association between tissue hypoattenuation and age. 
Moreover, the relation between age and symptomatic 
intracerebral haemorrhage could be more complex 
than initially thought. The Safe Implementation of 
Thrombolysis in Stroke (SITS) registry has shown that 
the rate of symptomatic intracerebral haemorrhage 
increases with age up to 70 years, but not beyond.4 
Such a ceiling eﬀ ect could account for why IST-3 could 
not conﬁ rm the association of age with symptomatic 
intracerebral haemorrhage reported in previous trials 
that included younger patients.5  
Compared with other trials, the relatively high 
proportion of patients treated within 3 h in IST-3 is 
another likely explanation for the lack of association 
between tissue hypoattenuation and symptomatic 
intracerebral haemorrhage in multivariate analysis, 
because tissue hypoattenuation becomes more 
discernible with time from stroke onset. The association 
between tissue hypoattenuation and symptomatic 
intracerebral haemorrhage was signiﬁ cant in previous 
European Cooperative Acute Stroke Study (ECASS) trials, 
in which patients were included up to 6 h after symptom 
onset, but not in the National Institute of Neurological 
Disorders and Stroke (NINDS) trial, in which patients 
were included within 3 h of symptom onset.6,7 Wardlaw 
and colleagues did analyses by time windows, which 
suggested that hypoattenuation was associated with 
symptomatic intracerebral haemorrhage in patients 
treated 4·5–6 h after stroke but not in those treated 
earlier, but these ﬁ ndings must be interpreted cautiously 
because of small samples and wide CIs.
Wardlaw and colleagues from the IST-3 collaborative 
group have identiﬁ ed some CT imaging ﬁ ndings 
that might help to estimate the risk of symptomatic 
intracerebral haemorrhage and reduced independence 
for the individual patient. However, no imaging ﬁ ndings, 
either alone or in combination, were associated with 
a modiﬁ ed treatment eﬀ ect of alteplase. The primary 
ﬁ ndings in IST-3 have contributed to the justiﬁ cation of 
extending treatment to patients older than 80 years in 
clinical practice. This new analysis suggests that patients 
who can be treated within 4·5 h might be considered 
for treatment irrespective of CT ﬁ ndings, as long as 
intracranial haemorrhage and established cerebral 
infarction have been excluded, although further studies 
will be needed to conﬁ rm these ﬁ ndings.
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Multiple scleros is drugs: how much bang for the buck?
Medical progress for patients with relapsing-remitting 
multiple sclerosis has been truly remarkable in the past 
two decades. So far, 12 disease-modifying therapies 
(DMTs) have been approved for this disorder, although 
regulatory approval varies by country. Given the 
successful performance of these agents in the clinical 
trial programmes that led to their approval, one has to 
wonder whether any regulatory agency or insurance 
carrier should require proof of eﬃ  cacy beyond the 
regulatory approval data.
In 2002, the UK’s National Institute for Clinical 
Excellence concluded that interferon beta-1a, interferon 
beta-1b, and glatiramer acetate would be cost eﬀ ective 
only if the short-term disability beneﬁ ts reported in clinical 
trials were maintained over an extended period in clinical 
practice. This conclusion seems reasonable, because 
safety and eﬃ  cacy in trial populations are often diﬀ erent 
from the results achieved in real-world clinical settings.1 
Consequently, the UK Multiple Sclerosis Risk Sharing 
Scheme (RSS) was established to assess whether disability 
progression as measured by the expanded disability status 
scale (EDSS) was consistent with a cost-eﬀ ectiveness 
target of £36 000 per quality-adjusted life-year. In The 
Lancet Neurology, Jacqueline Palace and colleagues2 report 
ﬁ ndings from an analysis of eﬀ ectiveness and cost-
eﬀ ectiveness of glatiramer aceteate, interferon beta-1b, 
and two formulations of interferon beta-1a over the ﬁ rst 
6 years of the UK’s RSS. 5610 patients with relapsing-
remitting multiple sclerosis starting a DMT were enrolled 
in the scheme, of whom 4304 were included in Palace 
and colleagues’ analysis. The researchers compared EDSS 
progression at 6 years with untreated EDSS progression 
modelled with data from the British Columbia multiple 
sclerosis database, using continuous Markov and 
multilevel models.3 An aggregate progression ratio for 
utility (a measure based on EDSS scores and quality of life) 
for the four DMTs combined of 0·62 (62% by comparison 
with untreated patients, a 38% relative reduction) was 
used as a threshold for cost-eﬀ ectiveness. The utility 
ratios were consistent with cost-eﬀ ectiveness: the relative 
rate of progression for utility was 58·5% (Markov model) 
or 57·1% (multilevel model). Findings from the Markov 
model showed an EDSS progression ratio of 75·8% and 
the multilevel model showed an EDSS ratio of 60·0%, 
equivalent to a 24% and 40% relative reduction in 
progression, respectively. Sensitivity analyses assessing 
the potential for biases continued to show a beneﬁ cial 
eﬀ ect of interferon beta formulations and glatiramer 
acetate.
The issue underlying this research is whether the 
beneﬁ ts of individual drugs justify their enormous cost 
to health-care providers and patients. The US Census 
Bureau reported that US inﬂ ation-adjusted median 
household income was $51 939 in 2013. The number of 
medically-related personal bankruptcies in the US is well 
above 50% of all ﬁ lings. Families with health insurance 
reported average out-of pocket medical expenses 
of $17 749, whereas uninsured individuals averaged 
$26 971. In the USA, multiple sclerosis has the highest 
personal drug costs of any chronic disorder, an average 
of US$34 167 per year for each patient in 2009 (when 
the yearly price of DMTs was between $22 272 and 
$33 804).4,5 Prices have doubled or even tripled for some 
DMTs since 2009. Although the number of treatments 
has increased, this change has not led to the increased 
competition and thus decreased prices that might 
be expected from economics lessons on free-market 
capitalism. We are currently unable to assess the merits of 
a less expensive drug for, say, less severe disease, because 
nearly all agents are roughly the same price, irrespective 
